Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6424232 | 0.92 | MAPT (0.42) | SMN1; SMN2MAPTLMNAF10KDM2B | |
| SCHEMBL6421346 | 0.89 | MAPT (0.40) | MAPTLMNAF10GAAMEN1 | |
| SCHEMBL6424181 | 0.89 | F10 (0.39) | MAPTLMNAF10KDM2BGAA | |
| SCHEMBL6421727 | 0.87 | ACHE (0.41) | SMN1; SMN2MAPTLMNAKDM2BPOLB | |
| Hydrochloric Acid SCHEMBL6420510 | 0.87 | F10 (0.43) | MAPTLMNAF10GAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL6424224 | 0.86 | ACHE (0.41) | SMN1; SMN2MAPTLMNAKDM2BPOLB | |
| SCHEMBL6423165 | 0.84 | F10 (0.37) | MAPTLMNAF10GAA | |
| SCHEMBL6420537 | 0.84 | PKM (0.38) | MAPTLMNAF10KDM2BGAA | |
| SCHEMBL6424049 | 0.83 | ACHE (0.44) | SMN1; SMN2MAPTLMNAKDM2BPOLB | |
| SCHEMBL6419879 | 0.83 | MAPT (0.37) | MAPTLMNAF10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289953-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6784182-B2 | AND FACTOR XA INHIBITORS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20020151724-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151724-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | SMN1; SMN2 1756/4885MAPT 4835/4885LMNA 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.